Accuracy of Serologic Tests and HLA-DQ Typing for Diagnosing Celiac Disease

Hadithi, Muhammed; Blomberg, B. Mary E. von; Crusius, J. Bart A.; Bloemena, Elisabeth; Kostense, Pieter J.; Meijer, Jos W. R.; Mulder, Chris J.; Stehouwer, Coen D. A.; Peña, Amado Salvador

doi:10.7326/0003-4819-147-5-200709040-00003

Cited by 185 publications

(148 citation statements)

References 36 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…The production of EMA and ⁄ or tTGA is known to be essentially restricted to HLA-DQ2 and ⁄ or -DQ8 positive persons. 19,20 Although the existence of fluctuating coeliac antibody levels in children who are genetically predisposed for CD has previously been described, the underlying pathophysiological mechanism is not well understood yet. 12,[21][22][23][24] Previous research has suggested different explanations for fluctuating antibody levels, including environmental factors such as the increase in gluten intake and ⁄ or gastro-intestinal infections, e.g.…”

Section: Discussionmentioning

confidence: 99%

Childhood coeliac disease: towards an improved serological mass screening strategy

Esch

Csizmadia

Hoogstraten

et al. 2010

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Childhood coeliac disease: towards an improved serological mass screening strategy

Esch

Csizmadia

Hoogstraten

et al. 2010

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…A positive anti-tTG was found in 3.1%, and the prevalenc e of CD in the serologic ally sc reened sample was 2.3%. When a similar study was performed in a university hospital, the prevalenc e of CD was 3.5%, and a negative HLA-DQ type exc luded the diagnosis [52] . However, the "addition of HLA-DQ typing to TGA and EMA testing, and the addition of serologic al testing to HLA-DQ typing, provided the same measures of test performanc e as either testing strategy alone" [52] .…”

Section: Serologymentioning

confidence: 99%

Recent advances in celiac disease

Freeman

Chopra²,

Clandinin³

et al. 2011

WJG

View full text Add to dashboard Cite

Celiac disease now affects about one person in a hundred in Europe and North America. In this review, we consider a number of important and exciting recent developments, such as clinical associations, HLA-DQ2 and HLA-DQ8 predispositions, the concept of potential celiac disease, the use of new imaging/endoscopy techniques, and the development of refractory disease. This review will be of use to all internists, pediatricians and gastroenterologists.

show abstract

“…ese aberrant T-cells are thought to be the origin of enteropathy associated T-cell lymphomas (EATL), and RCD type II patients have thus an increased risk to develop an EATL. While antibodies against tissue transglutaminase (TG2A) are highly sensitive and speci c for the diagnosis of active CD [3], currently there are no biochemical parameters that can aid in the diagnosis of RCD; diagnosis relies on invasive endoscopic procedures.…”

Section: Introductionmentioning

confidence: 99%

Increased IgA Glycoprotein-2 Specic Antibody Titres in Refractory Celiac Disease

Groß

Bakker

Bodegraven

et al. 2014

JGLD

View full text Add to dashboard Cite

Background & Aims: In most cases celiac disease (CD) is successfully treated with a gluten-free diet (GFD). However, some patients become refractory to the GFD. Refractory CD (RCD) patients have an increased risk for developing enteropathy associated T-cell lymphoma and early diagnosis is therefore of importance. Currently, RCD diagnosis relies on endoscopy and adequate serological markers are lacking. Antibodies against glycoprotein-2 (GP2A) were described in Crohn's disease (CrD) and active CD but not in ulcerative colitis (UC), suggesting this is a specific marker for small intestinal lesions.Methods: Sera obtained from patients visiting our outpatient clinic for routine serological tests for diagnosis and/or follow-up of inflammatory bowel disease (n=78), active CD (n=45), GFD (n=34) and RCD (n=15) were analysed for GP2A titres.Results: Increased GP2A-IgA levels in CrD and active CD as compared to controls (p<0.001) and lack thereof in UC was confirmed. However, we could not confirm the association with small bowel localization within the CrD patient group. Within CD patients, we demonstrated a significant decrease of GP2A-IgA titres upon a GFD and increased levels in RCD patients as compared to patients on a GFD. Although GP2A-IgA was not associated with the degree of villous atrophy, GP2A-IgA levels were able to distinguish RCD patients from GFD patients (ROC AUC=0.79, p=0.002).Conclusion: Follow-up of GP2A-IgA titres in CD patients on a GFD may help to identify patients at risk for developing RCD.Abbreviations: ABSA: anti-bovine serum albumine; ASCA: anti- Saccharomyces cerevisiae antigen; AU:artificial units; AUC: area under the curve; CD: celiac disease; CrD: Crohn's disease; EATL: enteropathyassociated T-cell lymphoma; EmA: anti-endomysium antibodies; GFD: gluten free diet; GP2A: glycoprotein 2 antibodies; IEL: intraepithelial lymphocytes; RCD: refractory celiac disease; ROC: receiver operator curve; TG2A: transglutaminase-2 antibodies; UC: ulcerative colitis.

show abstract

Accuracy of Serologic Tests and HLA-DQ Typing for Diagnosing Celiac Disease

Cited by 185 publications

References 36 publications

Childhood coeliac disease: towards an improved serological mass screening strategy

Childhood coeliac disease: towards an improved serological mass screening strategy

Recent advances in celiac disease

Increased IgA Glycoprotein-2 Specic Antibody Titres in Refractory Celiac Disease

Contact Info

Product

Resources

About